Chimeric Antigen Receptor Comprising Third Signal Receptor for Cancer Therapy
Summary
The European Patent Office published patent application EP3812401A1 for Shanghai Longyao Biotechnology Inc., covering a chimeric antigen receptor (CAR) comprising a third signal receptor for cancer therapy. The application claims priority to the A61P 35/00 classification for antineoplastic agents. The patent is published with IPC classifications C07K 19/00 and A61K 48/00, with designated states covering all EU member states plus other European countries.
What changed
The EPO published patent application EP3812401A1 filed by Shanghai Longyao Biotechnology Inc., Ltd covering chimeric antigen receptor (CAR) technology incorporating a third signal receptor domain for enhanced cancer therapy. The application was published April 1, 2026, with IPC classifications in C07K 19/00, A61K 48/00, and A61P 35/00, designating all major European patent states.
For biotechnology and pharmaceutical companies developing CAR-T or similar immunotherapy platforms, this patent publication signals potential freedom-to-operate considerations in the European market. Competitors should monitor the prosecution of this application to understand the scope of claims granted, particularly regarding the third signal receptor configuration which may represent a novel advancement in CAR design.
What to do next
- Monitor for updates
- Review patent claims for freedom to operate
- Assess competitive landscape impact
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CHIMERIC ANTIGEN RECEPTOR COMPRISING THIRD SIGNAL RECEPTOR AND USE THEREOF
Publication EP3812401A1 Kind: A1 Apr 01, 2026
Applicants
Shanghai Longyao Biotechnology Inc., Ltd
Inventors
YANG, Xuanming, FU, Yangxin, WANG, Xin, YE, Shengqin, LI, Min
IPC Classifications
C07K 19/00 20060101AFI20220311BHEP A61K 48/00 20060101ALI20220311BHEP A61P 35/00 20060101ALI20220311BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.